Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review
Discussion: Combining checkpoint inhibitors and platinum-based therapies may result in AKI. The standard method of examining kidney tissue may not provide sufficient information about the effects of these drugs on the kidneys. To address this issue, we recommend incorporating an assessment of the analysis of the expression of PDL1 and p53. This personalized approach will help identify the best treatment option for the patient while ensuring the best possible cancer treatment plan.PMID:38610593 | DOI:10.3390/jcm13071828
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Nicoletta Mancianti Sergio Antonio Tripodi Alessandra Pascucci Marta Calatroni Edoardo La Porta Andrea Guarnieri Guido Garosi Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Nephritis | Non-Small Cell Lung Cancer | Urology & Nephrology